N-Acetyl Cysteine in Trichotillomania
Information source: University of Chicago
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Trichotillomania
Intervention: Placebo (Drug); N-Acetyl Cysteine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: University of Chicago Official(s) and/or principal investigator(s): Jon E Grant, MD, JD, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute
Summary
This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of
trichotillomania
Clinical Details
Official title: A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Massachusetts General Hospital Hairpulling Scale
Detailed description:
The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine
(NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks
of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective
and well tolerated in patients with trichotillomania compared to placebo. The proposed study
will provide needed data on the treatment of a disabling disorder that currently lacks a
clearly effective treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- men and women age 18-65;
- current DSM-IV trichotillomania
Exclusion Criteria:
- unstable medical illness;
- history of seizures;
- myocardial infarction within 6 months;
- current pregnancy or lactation, or inadequate contraception in women of childbearing
potential;
- any thoughts of suicide;
- lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any
other DSM-IV psychotic disorder;
- previous treatment with N-Acetyl Cysteine;
- treatment with investigational medication or depot neuroleptics within 3 months,
with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to
study baseline;
- 9) diagnosis of asthma
Locations and Contacts
University of Minnesota Medical Center, Minneapolis, Minnesota 55454, United States
Additional Information
Starting date: July 2006
Last updated: July 7, 2014
|